Joint Access Advisory Mechanism (JAAM) for the EU-funded Covid-19 platform trials

The JAAM is the single access point for developers and investigators to propose new and repurposed therapeutic solutions, treatment optimisation and combination strategies that can be evaluated in Phase II or Phase III trials. With an independent expert panel, the JAAM advises the EU funded COVID-19 platform trials EU-SolidAct, REMAP-CAP and ECRAID Prime in Europe.

Composition
The JAAM includes a panel of seven renowned experts that are fully independent from the EU-funded platform trials. The coordinators of the major EU funded Covid-19 clinical trials are observers of the JAAM.

How it works?
The JAAM meets regularly, to assess requests for access according to the following criteria:
1. Public health interest;
2. Scientific, medical and ethical soundness;
3. Appropriate patient population, comparator and outcomes;
4. Promotion of coordination and optimal use of resources.
Following its assessment, the JAAM emits recommendations to initiate negotiations for the trials based on the target population (ICU, ward, or outpatients), and the final decision on access is made with each trial’s coordinating bodies.

The JAAM is operated by

The clinical trials accessible through the JAAM are funded by the European Union Horizon 2020 and Horizon Europe Research and Innovation programmes under grant agreements: 101015736, 101003589, 101046109.